eTheRNA
eTheRNA develops immunotherapies that target the fundamental role of dendritic cells in the human immune system.
eTheRNA has raised €73M across 2 funding rounds from 7 investors, most recently a Series B round in Aug 2022. Based in Jette, Belgium; founded 2013; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€73M
€73,000,000
Funding rounds
2
Investors
7
distinct backers
Active since
2020-06
latest 2022-08
Funding by year
EUR raised per yeareTheRNA — funding by year — interactive chart.
Data table
| eTheRNA — funding by year | |
|---|---|
| 2020 | €34M |
| 2022 | €39M |
Signals
High confidenceRaise-next likelihood9
base rate 48% for Series B
- ▼ Past typical raise window
- ▼ Low backer re-investment
Exit likelihood9
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-08-29 | Series B | €39M | FundPlus,Grand Pharma,LSP,Novalis LifeSciences,Omega Funds,PMV+1 more | View deal → |
| 2020-06-18 | Series B | €34M | — | View deal → |
Related news
- eTheRNA Raises €39M in Series B2 Financingfinsmes.com · 2022-08
- labiotech.eu
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Imec€2.5BBelgium · Deeptech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Kpler€1.0BBelgium · Software
Global coverage: FundingData